In NK cells, tumor-derived and recombinant TGF-β1 has been shown to downregulate the expression of NKp30 and NKG2D activating receptors involved in tumor recognition and DC editing (16, 17) and to modulate the chemokine receptor repertoire. This evidence concerns the gene NCR3 and neoplasm.